Search Results for 'immuno-oncology'
-
Breaking News | Drug Development | Industry News
Innovent Biologics, Bolt Biotherapeutics Enter Immuno-oncology Alliance
Will leverage Innovent's therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolt's ISAC technology08.27.21
-
Collaborations & Alliances | Drug Development
Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance
Aims to develop and commercialize a family of human antibodies to inhibit the growth of tumor cells.07.07.21
-
-
Breaking News | Collaborations & Alliances | Drug Development
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.Contract Pharma Staff 09.04.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Drug Discovery | Industry News
Targovax, Valo Tx to Evaluate Virus Platforms in Tumors
Will test PeptiCRAd technology for enhanced immune activation with TG mutant RAS peptidesContract Pharma Staff 04.22.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
Servier Acquires Cancer Biotech Symphogen
Strengthens R&D pipeline by acquiring antibody pipeline and next-gen antibody technologiesContract Pharma Staff 04.07.20
-
Breaking News | Collaborations & Alliances | Drug Development
I-Mab, Kalbe Genexine Enter Strategic Pact
KG Bio will have option for exclusive rights to commercialize two I-Mab product candidates.03.31.20
-
Breaking News | Collaborations & Alliances | Drug Development
Lilly, Sitryx Enter Autoimmune Alliance
To develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.03.31.20
-
Bio News | Breaking News | cGMP Manufacture | Process Development
Immunogenesis, ProBioGen Enter Large-Scale Mfg. Pact
To provide cell line development, process development and GMP manufacture of Immunogenesis’ lead immuno-oncology candidate03.25.20
-
Breaking News | Collaborations & Alliances | Drug Development
Zydus, XOMA Enter IO Agreement
To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.03.09.20
-
Breaking News | Collaborations & Alliances | Industry News
Nexelis to Acquire ImmunXperts
The closing of the transaction is expected by the end of March03.05.20
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
zPREDICTA Enters Collaboration with LabCorp
Agreement advances use of 3D cell cultures in research and drug development03.03.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Avectas, CCRM Enter Cell Therapy Tie-up
Collaboration to accelerate development of novel technology for cell therapies03.03.20
-
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Gilead to Acquire Forty Seven for $4.9B
Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers03.02.20
-
Collaborations & Alliances | Drug Development | Drug Discovery | Information Technology
OSE Immunotherapeutics, MAbSilico Enter AI Alliance
To leverage innovative problem-solving solutions like AI for the development of new monoclonal antibodies02.12.20
-
-
-
-
Breaking News | Collaborations & Alliances | Drug Development
PhoreMost, Boehringer Enter Drug Discovery Alliance
Will leverage PhoreMost’s SITESEEKER platform to identify novel targets for Boehringer’s discovery programs01.14.20
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
Astellas, Adaptimmune Enter CAR-T Alliance
Aims to develop new stem-cell derived allogeneic T-cell therapies to treat cancer01.14.20
-
Bio News | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News | Process Development
Indapta, Lonza Form Immuno-oncology Partnership
Lonza to provide process development, clinical manufacturing and regulatory support for IND filing.01.13.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Scale-up/Technology Transfer
Biomica Enters Service Agreement with Biose Industrie
French CDMO to provide scale-up and GMP production of drug candidates for Biomica’s immuno-oncology program.01.13.20
-
Bio News | Drug Development | Industry News
Leap, BeiGene Ink Exclusive Antibody Alliance
To develop and commercialize Leap’s DKN-01 anti-Dickkopf-1 antibody in gastric cancer01.03.20
-
Drug Development | Industry News
Astellas Acquires Xyphos Biosciences
Gains novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform01.02.20
-
Drug Development | R&D
Top Pharma M&A Deals of 2019
Drug manufacturers spent a record $342 billion on Mergers & AcquisitionsOnline Exclusives Kristin Brooks, Contract Pharma 12.23.19
-
Breaking News | Drug Development | Industry News
Sanofi Acquires Synthorx in $2.5B Deal
CA-based immuno-oncology company expands Sanofi's cancer and autoimmune pipeline12.10.19
-
Breaking News | Collaborations & Alliances | Drug Discovery
IONTAS, Adaptate Enter Antibodies Alliance
To generate and optimize antibodies for novel immuno-oncology targets12.03.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Navrogen, Lonza Enter Bio Production Deal
Sign agreement to use Lonza’s GS Gene Expression System for Navrogen’s anti-HIO targeting agents.11.22.19
-
Breaking News | cGMP Manufacture | Industry News
Catalent, BeiGene Enter Long-Term Supply Agreement
Will manufacture BRUKINSA, a Bruton’s tyrosine kinase (BTK) inhibitor that recently received accelerated approval from the U.S. FDA.11.21.19
-
Breaking News | Drug Development | Industry News
ABL Bio, GenScript Enter Bispecific Antibody Alliance
GenScript will serve as ABL Bio’s exclusive supplier of CDMO services for IND-enabling studies and clinical material manufacturing11.19.19
-
Biologics, Proteins, Vaccines | Clinical Trials
Advanced Therapies: Adding a New Layer of Complexity to Clinical Trials
Overcoming the challenges of a new and changing clinical trial landscapeErin Finot, Global Head of Immuno-Oncology, IQVIA Biotech 11.18.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
ABL Bio, GenScript Enter Biologics Partnership
ABL appoints GenScript as the exclusive supplier of CDMO services.11.18.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
BioInvent, Cancer Research UK Sign Manufacturing Pact
Expected to generate approximately $3 million.10.23.19
-
Clinical Trials | Drug Development | Information Technology
Better Collaboration is Key to Speeding Trials
Clinical leaders discuss bringing together disparate processes and systems for improved collaboration and more efficient trial execution at Veeva R&D SummitOnline Exclusives Jim Reilly, vice president of clinical strategy at Veeva Systems 10.18.19
-
Breaking News | Drug Discovery | Industry News | Preclinical Outsourcing
BioIVT Acquires PPA Research Group
Expands product portfolio to support immuno-oncology and cell therapy research10.18.19
-
Escaping the Niche Career Box
Broaden your horizons to unlock your true growth potential.Ryan Raver, PhD, Contributing Editor 10.15.19
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Drug Discovery | Industry News
Astellas to Fund Boston-Area Cell and Gene Therapy Start-Up
Invests $12.5 million to support LabCentral Incubators in Boston's Life Science Community10.01.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
IRBM Signs Agreement with MD Anderson Cancer Center
To generate novel immune-checkpoint monoclonal antibodies09.10.19
-
Promotions & Moves
Marker Therapeutics Appoints Regulatory Affairs VP
Dr. Agopyan brings more than 15 years of industry knowledge in regulatory affairs and clinical development08.16.19
-
Promotions & Moves
TCR2 Therapeutics Expands Leadership Team
Aims to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells08.06.19
-
Drug Development | Industry News
Aquinox, Neoleukin Therapeutics Announce Merger Agreement
Combined company capitalized with approximately $65M to develop novel immunotherapies08.06.19
-
-
-
-
-
-
-
-
